A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
600
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

H. Lundbeck A/S